Clene Inc (CLNN) Stock Price, Quote & News

Company Profile

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic...

Industry: Packaged Foods

Sector: Consumer Defensive

Phone: 801 676 9695

Website: clene.com

Address:

6550 South Millrock Drive, Suite G50, Salt Lake City, United States

paule815 May. 16 at 10:23 AM

$CLNN Come on. This should be $20 now. Just let it runnnnnn!

0 · Reply

7m3835d3 May. 15 at 7:57 PM

$CLNN new headline..clnn stock rises mid day due to high probability of AA in early 2027

0 · Reply

vijaykamat14 May. 15 at 7:51 PM

$CLNN

0 · Reply

fibonacci1170 May. 15 at 6:37 PM

$CLNN I know CLENE has its plate full at the moment, but THIS is where CLNN's mcap can explode to $3500/share. I desperately want CLENE to PR: "we are initiating CNM-Au8 for Alzheimer's to restore NAD+ levels". That's it. https://www.newsnationnow.com/health/alzheimers-reverse-brain-molecule/?utm_source=flipboard&utm_content=user/NewsNationNow

2 · Reply

neuroinvestor3 May. 15 at 3:39 PM

$CLNN Our Roth Capital analyst, Jonathan Aschoff, had some questionable ethics.... page 9. Terminated from FBR for posing as a medical doctor to get patient clinical trial data. https://files.brokercheck.finra.org/individual/individual_4220184.pdf

1 · Reply

Fidia May. 15 at 1:26 PM

$CLNN Chidozie only has 100,000 shares left that he can sell. Once his selling streak is over, I don't think we'll be seeing the stock price below $7 anymore. The maturity date for the $10 million convertible notes has been extended, and the terms have been restructured to a bullet payment of both principal and interest at maturity. The new deadline is August 2027, with a conversion price set at $22. VCs do not make these kinds of bets on a failing company.

0 · Reply

Mulhollandr May. 15 at 12:48 PM

$CLNN the “stock price falls” headline is so f’n stupid. It was a couple thousand shares. And the “long shot” prediction still comes with a $30 price target, go figure.

2 · Reply

Acx21 May. 15 at 6:39 AM

$CLNN Don't worry guys this is a file dated on early January and as you can see in the text part "Comment for Type of Reporting Person", there is only the potential of 1.9m shares voting power: - 741,292 common stock: These are the ones sold over the last couple of months / around 100k remaining if not already sold yesterday or the day before (form 4 sellings) - 375,000 Tranche A warrants (strike price 22$, expire date 16.06.2026 or NDA + 60 days) - 375,000 Tranche B warrants (strike price 30$, expire date 16.06.2030 or NDA + 60 days) - 424,358 Common Stock Purchase Warrant (honestly I'm not sure about these, haven't read about them before - maybe somebody got some information about strike price/expire date??) So as you can see, there are currently only the 100k remaining - but he might join us shareholders later on again. But then at a price he most certainly don't want to sell anymore. Cause if we are >22$/>30$ there will be no more doubt about the commercial success of CNM-Aug8

0 · Reply

mikesterz7 May. 15 at 2:19 AM

$CLNN Clene said earlier on Thursday that it plans to submit a New Drug Application for its lead ALS candidate CNM-Au8 in the third quarter of 2026 under the FDA’s accelerated approval pathway.

0 · Reply

Woodman7 May. 15 at 1:09 AM

Source: TipRanks Financial $CLNN https://share.google/8lkZgZXQ8PN38usCz

0 · Reply

Roth says FDA approving Clene’s ALS treatment NDA a ‘long shot’

2026-05-14T16:30:10.000Z - 1 day ago

Clene reports Q1 EPS (69c), consensus (70c)

May 14, 2026, 8:00 AM EDT - 2 days ago

Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights

2026-05-08T11:23:32.000Z - 8 days ago

Clene price target raised to $50 from $48 at Canaccord

May 6, 2026, 3:25 PM EDT - 9 days ago

Clene Transcript: Emerging Growth Conference 92

May 5, 2026, 8:45 AM EDT - 11 days ago

Clene Announces $7 Million Underwritten Offering of Common Stock

May 5, 2026, 8:00 AM EDT - 11 days ago

Clene to Present at Upcoming May Conferences

2026-05-04T13:21:26.000Z - 12 days ago

Clene provides update on NDA for ALS following Type C meeting with FDA

May 4, 2026, 8:00 AM EDT - 12 days ago

After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS

2026-03-12T12:12:18.000Z - 2 months ago

Clene reports FY25 EPS ($2.65), consensus ($2.35)

Mar 12, 2026, 8:00 AM EDT - 2 months ago

Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights

Feb 25, 2026, 1:45 PM EST - 2 months ago

Clene Transcript: Emerging Growth Virtual Conference

2026-02-24T13:13:07.000Z - 2 months ago

Clene issues letter to shareholders on CNM-Au8 2026 catalysts

Feb 24, 2026, 8:00 AM EST - 2 months ago

Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts

Feb 19, 2026, 8:30 AM EST - 3 months ago

Clene to Present at the Emerging Growth Conference

Jan 21, 2026, 3:10 PM EST - 4 months ago

Clene Transcript: Emerging Growth Conference 89

2026-01-12T14:08:41.000Z - 4 months ago

Clene announces additional CNM-Au8 biomarker data for potential NDA filing

Jan 12, 2026, 8:30 AM EST - 4 months ago

Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting

2026-01-09T13:41:01.000Z - 4 months ago

Clene announces over $28M registered direct offering

Jan 9, 2026, 8:30 AM EST - 4 months ago

Clene Announces Registered Direct Offering of Over $28 Million

Dec 10, 2025, 4:25 PM EST - 5 months ago

Clene Transcript: Emerging Growth Conference 88

2025-12-03T18:15:36.000Z - 5 months ago

Clene price target raised to $30 from $20 at Maxim

Dec 3, 2025, 8:30 AM EST - 5 months ago

Clene Transcript: Study Update

2025-12-03T13:15:33.000Z - 5 months ago

Clene announces significant reductions in NfL, GFAP when treated with CNM-Au8

Dec 3, 2025, 8:00 AM EST - 5 months ago

Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®

Dec 2, 2025, 5:39 PM EST - 5 months ago

Clene to Provide CNM-Au8® ALS Program Update

Nov 20, 2025, 8:00 AM EST - 6 months ago

Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference

2025-11-13T13:10:28.000Z - 6 months ago

Clene reports Q3 EPS (85c), consensus (56c)

2025-11-13T13:10:16.000Z - 6 months ago

Clene sees cash runway into 2Q26

Nov 13, 2025, 8:00 AM EST - 6 months ago

Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights

Oct 23, 2025, 3:10 PM EDT - 7 months ago

Clene Transcript: Emerging Growth Conference

Oct 15, 2025, 8:30 AM EDT - 7 months ago

Clene to Participate in a Panel Discussion at the Maxim Growth Summit

2025-09-25T12:10:32.000Z - 8 months ago

Clene announces presentation of combined REPAIR-MS results

Sep 25, 2025, 8:00 AM EDT - 8 months ago

Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients

2025-09-10T12:00:43.000Z - 8 months ago

Clene price target lowered to $31 from $33 at Benchmark

2025-09-05T20:20:08.000Z - 9 months ago

Clene files to sell 491,496 shares of common stock for holders

Sep 5, 2025, 7:00 AM EDT - 9 months ago

Clene Transcript: H.C. Wainwright 27th Annual Global Investment Conference

2025-09-04T12:46:04.000Z - 9 months ago

Clene presents preclinical data supporting CNM-Au8 for Parkinson’s disease

2025-09-04T12:45:58.000Z - 9 months ago

Clene presents preclinical data supporting CNM-Au8 for Parkinson’s disease

Sep 4, 2025, 8:30 AM EDT - 9 months ago

Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson's Disease

Sep 2, 2025, 8:00 AM EDT - 9 months ago

Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 2:20 PM EDT - 9 months ago

Clene Transcript: Emerging Growth Conference 85

2025-08-18T10:40:11.000Z - 9 months ago

Clene price target lowered to $48 from $83 at Canaccord

2025-08-14T12:45:43.000Z - 9 months ago

Clene reports Q2 EPS (78c) vs ($1.06) last year

Aug 14, 2025, 8:38 AM EDT - 9 months ago

Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights

Aug 12, 2025, 3:30 PM EDT - 9 months ago

Clene Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 5, 2025, 8:30 AM EDT - 10 months ago

Clene to Present at the Canaccord 45th Annual Growth Conference

Jul 17, 2025, 3:10 PM EDT - 10 months ago

Clene Transcript: Emerging Growth Conference 84

2025-06-30T14:38:15.000Z - 11 months ago

Clene provides regulatory update following FDA Type C meeting

Jun 30, 2025, 8:00 AM EDT - 11 months ago

Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings

Jun 10, 2025, 1:00 PM EDT - 1 year ago

Clene Transcript: Q2 Virtual Investor Summit Event

Jun 9, 2025, 9:00 AM EDT - 1 year ago

Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025

May 21, 2025, 3:10 PM EDT - 1 year ago

Clene Transcript: Emerging Growth Conference 82

May 7, 2025, 8:00 AM EDT - 1 year ago

Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

Apr 1, 2025, 8:30 AM EDT - 1 year ago

Clene to Present at the Jones Healthcare and Technology Innovation Conference

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights

Mar 18, 2025, 12:30 PM EDT - 1 year ago

Clene Transcript: 37th Annual ROTH Conference

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment

Mar 6, 2025, 8:30 AM EST - 1 year ago

Clene to Present at the 37TH Annual Roth Conference

Feb 27, 2025, 9:15 AM EST - 1 year ago

Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11

Feb 25, 2025, 8:00 AM EST - 1 year ago

Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction

Dec 10, 2024, 8:30 AM EST - 1 year ago

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

Sep 30, 2024, 8:30 AM EDT - 1 year ago

Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules

Sep 16, 2024, 8:30 AM EDT - 1 year ago

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 8:00 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.

Aug 7, 2024, 8:23 AM EDT - 1 year ago

Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights

Jul 11, 2024, 9:00 AM EDT - 2 years ago

Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS

Jul 9, 2024, 8:00 AM EDT - 2 years ago

Clene Announces 1-for-20 Reverse Stock Split

Jun 24, 2024, 8:00 AM EDT - 2 years ago

Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference

Jun 21, 2024, 7:09 AM EDT - 2 years ago

Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

Jun 18, 2024, 7:00 AM EDT - 2 years ago

Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting

May 28, 2024, 7:30 AM EDT - 2 years ago

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)

May 8, 2024, 8:00 AM EDT - 2 years ago

Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights

Apr 16, 2024, 4:01 PM EDT - 2 years ago

Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting

Mar 15, 2024, 8:00 AM EDT - 2 years ago

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

Feb 29, 2024, 8:00 AM EST - 2 years ago

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

Dec 21, 2023, 11:25 AM EST - 2 years ago

Clene says FDA finds ALS drug data not enough for accelerated nod

Dec 21, 2023, 7:00 AM EST - 2 years ago

Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension

Dec 21, 2023, 7:00 AM EST - 2 years ago

Clene Provides Update on ALS Clinical Development Meeting With FDA

Dec 14, 2023, 8:36 AM EST - 2 years ago

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

Nov 7, 2023, 8:00 AM EST - 2 years ago

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

paule815 May. 16 at 10:23 AM

$CLNN Come on. This should be $20 now. Just let it runnnnnn!

0 · Reply

7m3835d3 May. 15 at 7:57 PM

$CLNN new headline..clnn stock rises mid day due to high probability of AA in early 2027

0 · Reply

vijaykamat14 May. 15 at 7:51 PM

$CLNN

0 · Reply

fibonacci1170 May. 15 at 6:37 PM

2 · Reply

neuroinvestor3 May. 15 at 3:39 PM

1 · Reply

Fidia May. 15 at 1:26 PM

0 · Reply

Mulhollandr May. 15 at 12:48 PM

$CLNN the “stock price falls” headline is so f’n stupid. It was a couple thousand shares. And the “long shot” prediction still comes with a $30 price target, go figure.

2 · Reply

Acx21 May. 15 at 6:39 AM

0 · Reply

mikesterz7 May. 15 at 2:19 AM

$CLNN Clene said earlier on Thursday that it plans to submit a New Drug Application for its lead ALS candidate CNM-Au8 in the third quarter of 2026 under the FDA’s accelerated approval pathway.

0 · Reply

Woodman7 May. 15 at 1:09 AM

Source: TipRanks Financial $CLNN https://share.google/8lkZgZXQ8PN38usCz

0 · Reply

StocktwitsNews May. 15 at 12:48 AM

CLNN Stock Falls After Roth Labels Accelerated Approval For ALS Drug A ‘Long Shot’ $CLNN $VTI $VXF https://stocktwits.com/news/equity/markets/clnn-stock-falls-after-roth-labels-accelerated-approval-for-als-drug-a-long-shot/cZXlh1zReSZ

0 · Reply

kcresskill12345 May. 14 at 11:53 PM

$CLNN you guys killing me. For anyone confused about the new 13G: It still shows Chidozie holding 1.9M shares because the filing reflects ownership as of 3/31/26, not today. His Form 4s tell the real story — he’s been selling for months and is down to around 100K. 13G = historical snapshot Form 4 = real‑time Nothing mysterious here, just SEC timing.

1 · Reply

Mulhollandr May. 14 at 9:32 PM

$CLNN holy 13 g/a plot twist Wtf is going on?! https://www.sec.gov/Archives/edgar/data/1822791/000183554426000020/xslSCHEDULE_13G_X02/primary_doc.xml

2 · Reply

Fidia May. 14 at 9:15 PM

$CLNN His returns are even worse than just investing in an index fund. haha.

0 · Reply

Bbbb44444 May. 14 at 8:25 PM

$CLNN How is the sentiment here “bearish.” I swear ST is a great counter-indicator.

0 · Reply

Mulhollandr May. 14 at 8:12 PM

$CLNN anyone have access to the Roth report that just hit the news feed?

1 · Reply

Kdg825 May. 14 at 7:57 PM

$CLNN letttass gooo

0 · Reply

Mulhollandr May. 14 at 7:56 PM

$CLNN I meant $1 dollar!🤣

0 · Reply

HodlMaBeer May. 14 at 7:30 PM

$CLNN nice pick up today

0 · Reply

Mulhollandr May. 14 at 6:34 PM

$CLNN maybe if I say it’s gonna drop into the $2S it’ll jump back into double digits?🤔🤣

1 · Reply

neuroinvestor3 May. 14 at 5:30 PM

$CLNN based on the size and timing of past Chidozie sales, when do we think he’ll be done?

1 · Reply

Mulhollandr May. 14 at 4:31 PM

$CLNN I’ve got 5 bucks on us closing at $6.50 again today.

2 · Reply

Market Cap	83.04M
Revenue (ttm)	200,000.00
Net Income (ttm)	-26.17M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-13,085.00%
Debt to Equity Ratio	-0.21

Volume	151,500
Avg Vol	588,344
Day's Range	N/A - N/A
Shares Out	11.78M
Stochastic %K	69%
Beta	0.89
Analysts	Strong Sell
Price Target	$30.71